Lucinactant approved for premie RDS
(Surfaxin, Discovery Laboratories)
Efficacy. While lucinactant's efficacy was evaluated in 2 randomized controlled trials, the trial dubbed SELECT (Safety and Effectiveness of Lucinactant vs. Exosurf in a Clinical Trial), was the pivotal phase 3 RDS prevention study that gained the drug U.S. marketing approval. The SELECT trial was a randomized trial of 1,294 premature infants (600 g to 1,250 g at birth) that compared lucinactant at a dose of 5.8 mL/kg given up to 4 times (N=524) to colfosceril palmitate (Exosurf, which is no longer marketed in the United States) (N=506) or beractant (N=258) administered at FDA-recommended doses. Compared to colfosceril palmitate, lucinactant demonstrated significant improvement in the proportion of premature infants suffering from RDS (defined as having a chest X-ray consistent with RDS and a FiO2 ≥0.30) at 24 hours after birth (39% vs 47%, P<.01) and lower RDS-related mortality through 2 weeks (5% vs 9%, P<.01).
Safety. In SELECT, the most common adverse effects of lucinactant are related to its administration down a premature infant's endotracheal tube and include endotracheal tube reflux (18 events per 100 doses), skin paleness (9 events per 100 doses), and endotracheal tube obstruction (6 events per 100 doses), often resulting in infants' needing a dose interruption (9 events per 100 doses). Administration-related adverse reactions were more common in premature infants receiving lucinactant compared to control surfactants. Oxygen desaturation was reported in 17%, 9%, and 13%, and bradycardia for 5%, 2%, and 3% of infants treated with lucinactant, colfosceril palmitate, and beractant, respectively.
Dosing. The recommended dose of lucinactant is 5.8 mL/kg birthweight administered by intratracheal administration. Up to 4 doses of lucinactant can be administered in the first 48 hours of life; however, doses should be given no more frequently than every 6 hours. Dosing should be interrupted if administration-related adverse reactions occur.